These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 18506577)

  • 1. 2D and 3D QSAR studies of diarylpyrimidine HIV-1 reverse transcriptase inhibitors.
    Rebehmed J; Barbault F; Teixeira C; Maurel F
    J Comput Aided Mol Des; 2008 Nov; 22(11):831-41. PubMed ID: 18506577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: SAR and Lead Optimization Using CoMFA and CoMSIA Studies (1995-2016).
    Vanangamudi M; Poongavanam V; Namasivayam V
    Curr Med Chem; 2017 Nov; 24(34):3774-3812. PubMed ID: 28685686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3D-QSAR analysis of a series of S-DABO derivatives as anti-HIV agents by CoMFA and CoMSIA.
    Xu HR; Fu L; Zhan P; Liu XY
    SAR QSAR Environ Res; 2016 Dec; 27(12):999-1014. PubMed ID: 27667445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular docking and 3D-QSAR studies on triazolinone and pyridazinone, non-nucleoside inhibitor of HIV-1 reverse transcriptase.
    Sivan SK; Manga V
    J Mol Model; 2010 Jun; 16(6):1169-78. PubMed ID: 20013136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Docking-based CoMFA and CoMSIA studies on naphthyl-substituted diarylpyrimidines as NNRTIs.
    Wu HQ; Yao J; He QQ; Chen FE
    SAR QSAR Environ Res; 2014; 25(10):761-75. PubMed ID: 25242254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of 3D-QSAR, Pharmacophore, and Molecular Docking in the Molecular Design of Diarylpyrimidine Derivatives as HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors.
    Liu G; Wang W; Wan Y; Ju X; Gu S
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29751616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docking, molecular dynamics and quantitative structure-activity relationship studies for HEPTs and DABOs as HIV-1 reverse transcriptase inhibitors.
    Mao Y; Li Y; Hao M; Zhang S; Ai C
    J Mol Model; 2012 May; 18(5):2185-98. PubMed ID: 21947448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computer-aided molecular design of highly potent HIV-1 RT inhibitors: 3D QSAR and molecular docking studies of efavirenz derivatives.
    Pungpo P; Saparpakorn P; Wolschann P; Hannongbua S
    SAR QSAR Environ Res; 2006 Aug; 17(4):353-70. PubMed ID: 16920659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CoMFA 3D-QSAR analysis of HIV-1 RT nonnucleoside inhibitors, TIBO derivatives based on docking conformation and alignment.
    Zhou Z; Madura JD
    J Chem Inf Comput Sci; 2004; 44(6):2167-78. PubMed ID: 15554687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3D-QSAR and docking studies on the HEPT derivatives of HIV-1 reverse transcriptase.
    Latha RS; Vijayaraj R; Singam ER; Chitra K; Subramanian V
    Chem Biol Drug Des; 2011 Sep; 78(3):418-26. PubMed ID: 21689378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revealing the drug-resistant mechanism for diarylpyrimidine analogue inhibitors of HIV-1 reverse transcriptase.
    Zhang H; Qin F; Ye W; Li Z; Ma S; Xia Y; Jiang Y; Zhu J; Li Y; Zhang J; Chen HF
    Chem Biol Drug Des; 2011 Sep; 78(3):427-37. PubMed ID: 21696545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of novel DABO derivatives as HIV-1 RT inhibitors using molecular docking, molecular dynamics simulations and ADMET properties.
    Zhang Y; Chen L; Wang Z; Zhu Y; Jiang H; Xu J; Xiong F
    J Biomol Struct Dyn; 2024 May; 42(8):4196-4213. PubMed ID: 37272892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CoMFA and CoMSIA 3D QSAR and docking studies on conformationally-restrained cinnamoyl HIV-1 integrase inhibitors: exploration of a binding mode at the active site.
    Buolamwini JK; Assefa H
    J Med Chem; 2002 Feb; 45(4):841-52. PubMed ID: 11831895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docking-based 3D-QSAR analyses of pyrazole derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Cichero E; Fossa P
    J Mol Model; 2012 Apr; 18(4):1573-82. PubMed ID: 21805124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docking-based 3D-QSAR and pharmacophore studies on diarylpyrimidines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Liu G; Wan Y; Wang W; Fang S; Gu S; Ju X
    Mol Divers; 2019 Feb; 23(1):107-121. PubMed ID: 30051344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3D-QSAR models on clinically relevant K103N mutant HIV-1 reverse transcriptase obtained from two strategic considerations.
    San Juan AA
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1181-94. PubMed ID: 18155520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor- and ligand-based 3D-QSAR study for a series of non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Hu R; Barbault F; Delamar M; Zhang R
    Bioorg Med Chem; 2009 Mar; 17(6):2400-9. PubMed ID: 19250835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 3D QSAR study of a series of HEPT analogues: the influence of conformational mobility on HIV-1 reverse transcriptase inhibition.
    Kireev DB; Chrétien JR; Grierson DS; Monneret C
    J Med Chem; 1997 Dec; 40(26):4257-64. PubMed ID: 9435895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variable selection based QSAR modeling on Bisphenylbenzimidazole as Inhibitor of HIV-1 reverse transcriptase.
    Kumar S; Tiwari M
    Med Chem; 2013 Nov; 9(7):955-67. PubMed ID: 23106285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three-dimensional quantitative structure-activity relationships study on HIV-1 reverse transcriptase inhibitors in the class of dipyridodiazepinone derivatives, using comparative molecular field analysis.
    Pungpo P; Hannongbua S
    J Mol Graph Model; 2000 Dec; 18(6):581-90, 601. PubMed ID: 11155314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.